Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Secondarily Infected Traumatic Lesions”

8 trials

Showing 8 of 8 results

Large-scale testing (Phase 3)Study completedNCT04155203
What this trial is testing

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions

Who this might be right for
Secondarily Infected Traumatic Skin Lesions
Padagis LLC 657
Large-scale testing (Phase 3)Study completedNCT00852540
What this trial is testing

Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

Who this might be right for
Skin Infections, Bacterial
Stiefel, a GSK Company 410
Large-scale testing (Phase 3)Study completedNCT00684177
What this trial is testing

Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)

Who this might be right for
Skin Infections, Bacterial
GlaxoSmithKline 508
Testing effectiveness (Phase 2)Study completedNCT01005771
What this trial is testing

Study to Assess the Efficacy and Safety of GF-001001-00 Cream in Secondarily-Infected Traumatic Lesions

Who this might be right for
Secondarily Infected Traumatic Lesions
Ferrer Internacional S.A. 200
Not applicableStudy completedNCT01445600
What this trial is testing

ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)

Who this might be right for
Skin Infections, Bacterial
GlaxoSmithKline 3,612
Testing effectiveness (Phase 2)Study completedNCT00626795
What this trial is testing

Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)

Who this might be right for
ImpetigoSecondarily Infected Traumatic Lesions
LEO Pharma 773
Early research (Phase 1)Study completedNCT01876550
What this trial is testing

Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.

Who this might be right for
Secondarily Infected Traumatic Skin Lesions
Sun Pharmaceutical Industries, Inc. 1,902
Testing effectiveness (Phase 2)Study completedNCT00758862
What this trial is testing

The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo

Who this might be right for
Secondarily Infected Traumatic Lesions (SITL)Impetigo
LEO Pharma 20

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation